U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Grade 3 Follicular Lymphoma

MedGen UID:
79093
•Concept ID:
C0280185
•
Neoplastic Process
Synonyms: Recurrent Follicular Large Cell Lymphoma; Recurrent Grade III Follicular Large Cell Lymphoma; Recurrent Grade III Follicular Lymphoma; Relapsed Follicular Large Cell Lymphoma; Relapsed Grade III Follicular Large Cell Lymphoma; Relapsed Grade III Follicular Lymphoma

Definition

The reemergence of grade 3 follicular lymphoma after a period of remission. [from NCI]

Professional guidelines

PubMed

Follicular lymphoma: 2023 update on diagnosis and management.
Jacobsen E
Am J Hematol 2022 Dec;97(12):1638-1651. Epub 2022 Oct 18 doi: 10.1002/ajh.26737. PMID: 36255040
Follicular lymphoma: an update on diagnosis, prognosis, and management.
Mozas P, Sorigué M, López-Guillermo A
Med Clin (Barc) 2021 Nov 12;157(9):440-448. Epub 2021 Jun 29 doi: 10.1016/j.medcli.2021.03.041. PMID: 34210513
Follicular lymphoma: 2020 update on diagnosis and management.
Freedman A, Jacobsen E
Am J Hematol 2020 Mar;95(3):316-327. Epub 2019 Dec 22 doi: 10.1002/ajh.25696. PMID: 31814159

Recent clinical studies

Etiology

DLBCL arising from indolent lymphomas: How are they different?
Parry EM, Roulland S, Okosun J
Semin Hematol 2023 Nov;60(5):277-284. Epub 2023 Nov 23 doi: 10.1053/j.seminhematol.2023.11.002. PMID: 38072721
Follicular lymphoma: 2023 update on diagnosis and management.
Jacobsen E
Am J Hematol 2022 Dec;97(12):1638-1651. Epub 2022 Oct 18 doi: 10.1002/ajh.26737. PMID: 36255040
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma.
Salles G, Schuster SJ, Dreyling M, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith SM, Jiménez-Ubieto A, Davis KL, Anjos C, Chu J, Zhang J, Lobetti Bodoni C, Thieblemont C, Fowler NH, Dickinson M, Martínez-López J, Wang Y, Link BK
Blood Adv 2022 Nov 22;6(22):5835-5843. doi: 10.1182/bloodadvances.2022008150. PMID: 35973192Free PMC Article
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Cheah CY, Wei MC, Yin S, Li CC, Huang H, Kwan A, Penuel E, Bartlett NL
Lancet Oncol 2022 Aug;23(8):1055-1065. Epub 2022 Jul 5 doi: 10.1016/S1470-2045(22)00335-7. PMID: 35803286
Antibody Therapy Maintenance in Follicular Lymphoma.
Golfier C, Salles G
Hematol Oncol Clin North Am 2020 Aug;34(4):689-699. Epub 2020 May 5 doi: 10.1016/j.hoc.2020.02.005. PMID: 32586574

Diagnosis

Follicular lymphoma: 2023 update on diagnosis and management.
Jacobsen E
Am J Hematol 2022 Dec;97(12):1638-1651. Epub 2022 Oct 18 doi: 10.1002/ajh.26737. PMID: 36255040
Follicular lymphoma: an update on diagnosis, prognosis, and management.
Mozas P, Sorigué M, López-Guillermo A
Med Clin (Barc) 2021 Nov 12;157(9):440-448. Epub 2021 Jun 29 doi: 10.1016/j.medcli.2021.03.041. PMID: 34210513
Antibody Therapy Maintenance in Follicular Lymphoma.
Golfier C, Salles G
Hematol Oncol Clin North Am 2020 Aug;34(4):689-699. Epub 2020 May 5 doi: 10.1016/j.hoc.2020.02.005. PMID: 32586574
Follicular lymphoma: 2020 update on diagnosis and management.
Freedman A, Jacobsen E
Am J Hematol 2020 Mar;95(3):316-327. Epub 2019 Dec 22 doi: 10.1002/ajh.25696. PMID: 31814159
How I manage patients with follicular lymphoma.
Casulo C
Br J Haematol 2019 Aug;186(4):513-523. Epub 2019 Jun 7 doi: 10.1111/bjh.16011. PMID: 31173345

Therapy

Follicular lymphoma: 2023 update on diagnosis and management.
Jacobsen E
Am J Hematol 2022 Dec;97(12):1638-1651. Epub 2022 Oct 18 doi: 10.1002/ajh.26737. PMID: 36255040
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Cheah CY, Wei MC, Yin S, Li CC, Huang H, Kwan A, Penuel E, Bartlett NL
Lancet Oncol 2022 Aug;23(8):1055-1065. Epub 2022 Jul 5 doi: 10.1016/S1470-2045(22)00335-7. PMID: 35803286
Follicular lymphoma: 2020 update on diagnosis and management.
Freedman A, Jacobsen E
Am J Hematol 2020 Mar;95(3):316-327. Epub 2019 Dec 22 doi: 10.1002/ajh.25696. PMID: 31814159
Obinutuzumab in follicular lymphoma.
Martinez-Calle N, Figueroa-Mora R, Villar-Fernandez S, Marcos-Jubilar M, Panizo C
Drugs Today (Barc) 2016 Dec;52(12):643-651. doi: 10.1358/dot.2016.52.12.2550578. PMID: 28276536
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.
Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmüller G, Reinhardt C, Baeuerle PA, Kufer P
Science 2008 Aug 15;321(5891):974-7. doi: 10.1126/science.1158545. PMID: 18703743

Prognosis

Follicular lymphoma: 2023 update on diagnosis and management.
Jacobsen E
Am J Hematol 2022 Dec;97(12):1638-1651. Epub 2022 Oct 18 doi: 10.1002/ajh.26737. PMID: 36255040
Follicular lymphoma: an update on diagnosis, prognosis, and management.
Mozas P, Sorigué M, López-Guillermo A
Med Clin (Barc) 2021 Nov 12;157(9):440-448. Epub 2021 Jun 29 doi: 10.1016/j.medcli.2021.03.041. PMID: 34210513
Follicular lymphoma: 2020 update on diagnosis and management.
Freedman A, Jacobsen E
Am J Hematol 2020 Mar;95(3):316-327. Epub 2019 Dec 22 doi: 10.1002/ajh.25696. PMID: 31814159
How I treat early-relapsing follicular lymphoma.
Casulo C, Barr PM
Blood 2019 Apr 4;133(14):1540-1547. Epub 2019 Jan 30 doi: 10.1182/blood-2018-08-822148. PMID: 30700421
Transformed follicular lymphoma.
Fischer T, Zing NPC, Chiattone CS, Federico M, Luminari S
Ann Hematol 2018 Jan;97(1):17-29. Epub 2017 Oct 18 doi: 10.1007/s00277-017-3151-2. PMID: 29043381

Clinical prediction guides

Follicular lymphoma: 2023 update on diagnosis and management.
Jacobsen E
Am J Hematol 2022 Dec;97(12):1638-1651. Epub 2022 Oct 18 doi: 10.1002/ajh.26737. PMID: 36255040
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma.
Salles G, Schuster SJ, Dreyling M, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith SM, Jiménez-Ubieto A, Davis KL, Anjos C, Chu J, Zhang J, Lobetti Bodoni C, Thieblemont C, Fowler NH, Dickinson M, Martínez-López J, Wang Y, Link BK
Blood Adv 2022 Nov 22;6(22):5835-5843. doi: 10.1182/bloodadvances.2022008150. PMID: 35973192Free PMC Article
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Cheah CY, Wei MC, Yin S, Li CC, Huang H, Kwan A, Penuel E, Bartlett NL
Lancet Oncol 2022 Aug;23(8):1055-1065. Epub 2022 Jul 5 doi: 10.1016/S1470-2045(22)00335-7. PMID: 35803286
Follicular lymphoma: 2020 update on diagnosis and management.
Freedman A, Jacobsen E
Am J Hematol 2020 Mar;95(3):316-327. Epub 2019 Dec 22 doi: 10.1002/ajh.25696. PMID: 31814159
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.
Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmüller G, Reinhardt C, Baeuerle PA, Kufer P
Science 2008 Aug 15;321(5891):974-7. doi: 10.1126/science.1158545. PMID: 18703743

Recent systematic reviews

Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma.
Bosch F, Kuruvilla J, Vassilakopoulos TP, Maio DD, Wei MC, Zumofen MB, Nastoupil LJ
Clin Lymphoma Myeloma Leuk 2024 Feb;24(2):105-121. Epub 2023 Sep 28 doi: 10.1016/j.clml.2023.09.007. PMID: 37981564
Efficacy of Autologous Hematopoietic Stem Cell Transplantation versus Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation for Follicular Lymphoma: Systematic Review and Meta-Analysis.
Liu X, Zheng Y, Li H, Wang M, You MJ, Tian C
Oncology 2023;101(12):822-835. Epub 2023 Aug 18 doi: 10.1159/000532090. PMID: 37598665
Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data.
Zinzi A, Gaio M, Liguori V, Cagnotta C, Paolino D, Paolisso G, Castaldo G, Nicoletti GF, Rossi F, Capuano A, Rafaniello C
Pharmacol Res 2023 Apr;190:106742. Epub 2023 Mar 22 doi: 10.1016/j.phrs.2023.106742. PMID: 36963592
Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis.
Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherril B, Ruiz-Soto R, Kaye JA, Hamadani M
J Oncol Pharm Pract 2016 Oct;22(5):666-78. Epub 2015 Aug 28 doi: 10.1177/1078155215603230. PMID: 26320127
High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M, Reiser M, Borchmann P, Engert A, Skoetz N
Cochrane Database Syst Rev 2012 Jan 18;1:CD007678. doi: 10.1002/14651858.CD007678.pub2. PMID: 22258971

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...